

Prof. GIACOMO ZOPPINI

Curriculum vitae
ed
elenco delle pubblicazioni
2014

INDIRIZZO

Prof. Giacomo Zoppini
Via Monumento,12
37024 Negrar (VR)
tel. 045/7502145
cell. 3401730757
codice fiscale: ZPPGCM59C22G687O

LUOGO E DATA DI NASCITA

Piombino (Li), 22 Marzo, 1959

POSIZIONE PROFESSIONALE

Professore Associato (sette disciplinare: MED/013 Endocrinologia)
Dipartimento di Medicina
Università degli Studi di Verona

Dirigente Medico I livello
UOC di Endocrinologia, Diabetologia e Malattie del Metabolismo
Azienda Ospedaliera Universitaria Integrata Verona
Piazzale A.Stefani, 1
37126 Verona
Tel 045/8123748
Fax 045/8027314
E mail: giacomo.zoppini@univr.it

EDUCAZIONE

- 1978 - Maturità scientifica presso il Liceo Scientifico E. Fermi di Padova;
- 1985 - Laurea in Medicina e Chirurgia conseguita presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Padova (votazione di 110/110 e lode);
- 1985 (II session) Abilitazione alla Professione di medico-chirurgo. Università di Bologna;
- 1988 - Specializzazione in Diabetologia e Malattie del Ricambio conseguita presso l'Università degli Studi di Verona (votazione di 70/70 e lode);
- 1987-1990 Post doctoral Fellowship presso il Joslin Diabetes Center, Harvard University, Boston, MA, Usa;
- 1993 -- Dottorato di Ricerca in Scienze Endocrinologiche e Metaboliche conseguito presso l'Università di Modena;
- 2000 - Specializzazione in Cardiologia conseguita presso l'Università degli Studi di Verona (votazione 45/50);
- 2009- Specializzazione in Endocrinologia e Malattie del Metabolismo presso l'Università degli Studi di Brescia (50/50).

ESPERIENZA PROFESSIONALE

- 1982-1983 Studente interno, Istituto di Biochimica, Università di Padova;
- 1983-1985 Studente interno, Istituto di Patologia Medica, Università di Padova;
- 1986-1987 Servizio militare di leva in qualità di Sottotenente Medico presso l'Ospedale Militare di Verona;
- 1987-1990 Post doctoral Fellowship presso il Joslin Diabetes Center, Harvard University, Boston, MA, Usa;
- 1985-1994 Medico Frequentatore, Cattedra di Malattie del Metabolismo, Università di Verona;
- 1990-1994 Titolare di servizio di Guardia Medica presso la USSL n.45 di Asola (Mn);
- 1994-1996 Ricercatore non confermato Cattedra di Malattie del Metabolismo, Università di Verona;
- 1995 Dirigente di 1° livello, UOC di Endocrinologia e Malattie del Metabolismo, Azienda Ospedaliera Universitaria Integrata di Verona;
- 1997 Ricercatore confermato Cattedra di Malattie del Metabolismo, Università di Verona;
- 2009 Professore Aggregato;
- 2014 Professore Associato.

BORSE DI STUDIO

- 1979-1981 Borsa di studio dell'Università di Padova;
- 1987-1990 Fellowship presso il Joslin Diabetes Center, Boston, U.S.A.;
- 1994-2008 Fondi 60 % Università di Verona.

ATTIVITA' DIDATTICA

1994	Esercitazioni agli studenti del corso di laurea di Medicina e Chirurgia;
1995	Didattica tutoriale agli studenti del IV e V anno del corso di laurea di Medicina e Chirurgia;
1994	Esami del corso di laurea e di specialità;
1994	Correlatore di Tesi di laurea e di specialità;
1998	Scuola di Specializzazione in Endocrinologia e Malattie del Ricambio insegnamenti di: Epidemiologia della patologia metabolica (3° anno, indirizzo Endocrinologia). Epidemiologia della patologia metabolica (3° anno, indirizzo Andrologia). Diabetologia (3° anno, indirizzo Malattie del Ricambio e Diabetologia).
2000	Corso elettivo di Casi clinici in Endocrinologia;
2000-2010	Insegnamento di Medicina Interna al 1° e 2° anno del Corso di Laurea per Tecnico di Fisiopatologia Cardiocircolatoria e Perfusionazione Cardiovascolare;
2003-2004	Docente presso il Dottorato di Ricerca in Malattie Croniche e Degenerative, con sede amministrativa nell'Università di Verona;
2004	Docente presso il Dottorato di Ricerca in Scienze Mediche Cliniche e Sperimentali, con sede amministrativa nell'Università di Verona;
2010	Insegnamento di Endocrinologia e Malattie del Ricambio del tronco comune delle specialità chirurgiche;
1994	Attività nei Corsi di formazione e di aggiornamento;
1994	Attività organizzativa ed istituzionale;
Dal 2009	(dicembre) Professore Aggregato (a norma della legge n. 230/2005);
Dal 2014	Riconoscimento nazionale di "idoneità a professore di 2° fascia SSD_MED 013".

ATTIVITA' CLINICA

1983-1985	Internato in Patologia Medica (Direttore Prof. Gaetano Crepaldi), Istituti Ospedalieri di Padova.
1985-1994	Medico frequentatore in Diabetologia e Malattie del Ricambio (Direttore Prof. Michele Muggeo), Istituti Ospedalieri di Verona.
1994	Assistenza ai pazienti della Divisione Clinicizzata di Endocrinologia e Malattie del Metabolismo (Direttore Prof. Michele Muggeo e successivamente – a partire dal 01/11/2009 – dal Prof. Enzo Bonora), Azienda Ospedaliera Universitaria Integrata di Verona. -Attività di assistenza clinica in reparto (con responsabilità di letti di degenza ordinaria). -Attività di guardia diurna e di reperibilità notturna. -Attività ambulatoriale divisionale e di consulenza specialistica nei vari reparti ospedalieri.
2010	Incarico di alta specializzazione in "Cardiomiopatia Diabetica".
2011	Ambulatorio dedicato ai pazienti diabetici affetti da cardiopatia ischemica.

L'attività clinica ha riguardato tutta la patologia endocrino-metabolica, sia acuta che cronica, nonché la patologia internistica con particolare attenzione alle malattie cardiovascolari (di cui sono specialista).

Referente del Sistema Qualità e Accreditamento.

PRINCIPALI ATTIVITA' DI RICERCA

Alterazioni della membrana plasmatica e funzione del recettore insulinico
Fosforilazione del recettore insulinico
Lipidi di membrana e attività del recettore insulinico
Fosforilazioni in tirosina e attività di enzimi del metabolismo glucidico
Attività dell'insulina nei monociti
Epidemiologia del diabete, dei fattori di rischio cardiovascolare e della mortalità
Danno ossidativo e complicanze nel diabete tipo 1
Qualità della vita e metodologie educative nelle patologie croniche
Steatosi epatica
Metabolismo osseo nell'infezione da HIV
Disfunzione diastolica nel diabete tipo 1 e tipo 2.

LINGUE STRANIERE

Inglese scritto e parlato
Francese scritto e parlato

UTILIZZO DEL COMPUTER

Programmi principali di Office e Linux.
Programmazione in Python
SPSS per analisi statistiche

PARTECIPAZIONE A PROGETTI DI COOPERAZIONE EUROPEI

Cost Action B5 1994-1999. "Molecular mechanisms in the etiology of non-insulin dependent diabetes mellitus (NIDDM).

Studio internazionale R3i sul rischio cardiovascolare residuo nel Diabete (REALIST epidemiological survey on microvascular residual. Residual Risk Reduction initiative (R3i)).

REVISORE PER RIVISTE SCIENTIFICHE INTERNAZIONALI:

Acta Diabetologica
Arthritis Research & Therapy
Atherosclerosis
Cardiovascular Diabetes
Clinical Chemistry and Laboratory Medicine
Diabetes Care
Diabetologia
Diabetes/Metabolism research and reviews
Hepatology
Journal of Endocrinological Investigation
Journal of Diabetes and Its Complications
Journal of Hepatology
Journal of the European Academy of Dermatology and Venereology
Minerva Endocrinologica
Nutrition Metabolism Cardiovascular Disease
Plos One
The Scandinavian Journal of Clinical & Laboratory Investigation

ISCRIZIONE E CARICHE IN SOCIETÀ SCIENTIFICHE

Società Italiana di Diabetologia
Membro del Gruppo di Studio SID di Epidemiologia
Membro del Consiglio Direttivo SID, Sezione Veneto e Trentino Alto-Adige (2005-2008)
Membro del Consiglio Direttivo SIE, Sezione Veneto e Trentino Alto-Adige (2014-)

FINANZIAMENTI

PRIN: Genetica della nefropatia e del rischio cardiovascolare associato al diabete (2011-2013)

STUDI CLINICI

Verona Diabetes Study
Renal Insufficiency and Cardiovascular Events (RIACE) Study Group
The RAED2 Randomized Trial

**Impatto della Produzione Scientifica complessiva mediante utilizzo indice h di Hirsch ed Impact Factor
(dati aggiornati al 18/07/2014)**

- Scopus: lavori: 115; numero di citazioni complessive: 2294; h-index 30
- Web of Science: lavori: 127; numero di citazioni complessive: 2430 (medio 19.13); h-index 27
- Impact Factor (IF)-2013 complessivo dei lavori pubblicati e recensiti su Medline: 566,742
- Impact Factor (IF)-2013 medio per singolo lavoro pubblicato e recensito su Medline: 5,34

**MOLTEPLICI INVITI PER RELAZIONI & MODERAZIONI A WORKSHOPS E/O CONGRESSI
NAZIONALI ED INTERNAZIONALI**

LAVORI IN EXTENSO CENSITI DA CURRENT CONTENTS

- 1) Bonora E., Moghetti P., Querena M., Cigolini M., Cacciatori V., Carassai P., **Zoppini G.**, Muggeo M.
Enzimi nel metabolismo glucidico nell'obesità e nel diabete.
Min Endocrinol 13: 275-278, 1988
- 2) Bonora E., Moghetti P., Cacciatori V., Zenere M., Tosi F., Travia D., **Zoppini G.**, Perobelli L., Muggeo M.
Plasma concentrations of glucagon during hyperglycemic clamp with or without somatostatin infusion in obese subjects
Acta Diabetol 27: 309-314, 1990
- 3) Bonora E., Moghetti P., Querena M., Zenere M., Cacciatori V., Tosi f., Travia D., **Zoppini G.** and Muggeo M.
Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone.
J Endocrinol Invest 15: 1-11, 1992
- 4) **Zoppini G.** and Khan C.R.
Effect of phospholipase treatment on insulin receptor signal transduction.
Diabetologia 35: 109-115, 1992
- 5) Hauguel-DeMouzon S., Csermely P., **Zoppini G.**, and Kahn C.R.
Quantitative Dissociation Between EGF Effects on c-myc and c-fos Gene Expression, DNA Synthesis, and Epidermal Growth Factor Receptor Tyrosine Kinase Activity.
J Cell Physiol 150: 180-187, 1992
- 6) Muggeo M., Moghetti P., Querena M., Cacciatori V., **Zoppini G.**, Zenere M., Tosi F., Bonora E.
Mononuclear leukocytes from obese patients with type II diabetes have reduced activity of hexokinase, 6-phosphofructokinase and glucose-6-phosphate dehydrogenase.
Horm Metab Res 25: 160-164, 1993
- 7) **Zoppini G.**, Galante P., Zardini M. and Muggeo M.
Phosphotyrosine protein profiles in monocytes after insulin and IGF-1 stimulation.
Eur J Clin Invest 24: 275-278, 1994
- 8) Muggeo M., Verlato G., Bonora E., Bressan F., Giroto S., Corbellini M., Gemma M.L., Moghetti P., Zenere M., Cacciatori V., **Zoppini G.**, De Marco R.
The Verona Diabetes Study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality.
Diabetologia 38:318-325, 1995
- 9) **G.Zoppini**, G.Targher, T.Monauni, G.Faccini, E.Pasqualini, C.Martinelli, M.L.Zenari, M.Muggeo.
Increase in Circulating Products of Lipid Peroxidation in Smokers with IDDM.

Diabetes Care 19: 1233-1236, 1996

10) M.Muggeo, G.Verlato, E.Bonora, **G.Zoppini**, M.Corbellini, R.de Marco
Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus. The Verona Diabetes Study.

Circulation 96: 1750-1754, 1997.

11) **G.Zoppini**, P.Galante, M.Zardini, M.Muggeo

Insulin induces tyrosine desphosphorylation of 92 kDa protein in suspended monocytes.

J Endocrinol Invest 21: 93-97, 1998

12) R.de Marco, F.Locatelli, **G.Zoppini**, G.Verlato, E.Bonora, M.Muggeo

Cause-specific mortality in type 2 diabetes.

Diabetes Care 22, 756-761, 1999.

13) **G.Zoppini**, G.Verlato, E.Bonora, R.de Marco, M.Muggeo.

Attending the Diabetes Center is associated with a reduction in cardiovascular mortality among NIDDM patients: The Verona Diabetes Study.

Diab. Met. Res. Rev. 15: 170-174, 1999.

14) **G.Zoppini**, G.Targher, V.Cacciatori, A.Guerriero, M.Muggeo

Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients.

Diabetes Care 22, 1871-1874, 1999

15) M.Muggeo, **G.Zoppini**, E.Bonora, E.Brun, R.C.Bonadonna, P.Moggetti, G.Verlato.

Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients. The Verona Diabetes Study

Diabetes Care 23: 45-50, 2000.

16) G.Targher, L.Bertolini, L.Zenari, V.Cacciatori, M.Muggeo, G.Faccini, **G.Zoppini**

Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes.

Diabetes Care 23, 524-528, 2000

17) Brun E, Nelson RG, Bennet PH, Imperatore G, **Zoppini G**, Verlato G, Muggeo M. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 2000; 23: 1119-1123.

18) Cacciatori V, Gemma ML, Bellavere F, Castello R, De Gregori ME, **Zoppini G**, Thomaseth K, Moggetti P, Muggeo M. Power spectral analysis of heart rate in hypothyroidism.

European Journal of Endocrinology 143: 327-333, 2000

- 19) Targher G., Zenari L., Faccini G., Falezza G., Muggeo M., **Zoppini G.** Serum leptin concentrations in young smokers with type 1 diabetes.
Diabetes Care 24: 793-794, 2001.
- 20) Targher G., Zenari L., Bertolini L., Muggeo M., **Zoppini G.** Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 24: 956-957, 2001.
- 21) Targher G., Zenari L., Bertolini L., Falezza G., Muggeo M., **Zoppini G.** Plasma Homocysteine levels are associated with von Willebrand factor, soluble intercellular adhesion molecule-1, and soluble tumor necrosis factor- α receptors in young type 1 diabetic patients without clinical evidence of macrovascular complications. Diabetes Care; 24: 1496-1497: 2001.
- 22) **G.Zoppini**, G.Faccini, M.Muggeo, L.Zenari, Falezza G, G.Targher. Elevated plasma levels of soluble receptors of TNF- α and their association with smoking and microvascular complications in young adults with type 1 diabetes.
J Clin Endocrinol Metab 186: 3805-3808, 2001.
- 23) Brun E., **Zoppini G.**, Zamboni C., Bonora E., Muggeo M. Glucose instability is associated with a high level of circulating P-selectin. Diabetes Care; 24: 1685, 2001.
- 24) **G.Zoppini**, M.Carlini and M.Muggeo. Self-reported exercise and quality of life in young type 1 diabetic subjects.
Diab Nutr Metab 16: 77-80, 2003.
- 25) **G.Zoppini**, G.Verlato, C.Zamboni, E.Brun, E.Bonora, M.Muggeo. Body mass index and the risk of mortality in type II diabetic patients from Verona.
Int J Obes Relat Metab Disord 27: 281-285; 2003.
- 26) G.Verlato, **G.Zoppini**, E.Bonora, M.Muggeo. Mortality from site-specific malignancies in type 2 diabetic patients from Verona.
Diabetes Care 26: 1047-1051; 2003.
- 27) **G.Zoppini**. The role of general practitioners in epidemiological research.
Diab Nutr Metab 16: 191-193; 2003
- 28) C Venturi, **G Zoppini**, C Zamboni, M Muggeo. Insulin sensitivity and hepatic steatosis in obese subjects with normal glucose tolerance.
Nutr Metab Cardiovasc Dis 14: 200-204; 2004.
- 29) G Targher, L Bertolini, R Padovani, L Zenari, **G Zoppini**, G Falezza. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men.
Diabetes Care 27: 2498-2500; 2004.

- 30) **G Zoppini**, G Targher, C Venturi, C Zamboni, M Muggeo. Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals.
Clinical Endocrinology 61: 711-715; 2004
- 31) G Targher , **G Zoppini**.
Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications.
Diabetes Care 27: 1236; 2004
- 32) Nicolucci A, Giorgino R, Cucinotta D, **Zoppini G**, Muggeo M, Squatrito S, Corsi A, Lostia S, Pappalardo L, Benaduce E, Girelli A, Galeone F, Maldonato A, Perriello G, Pata P, Marra G, Coronel GA.
Validation of the Italian version of the WHO-Well-Being Questionnaire (WHO-WBQ) and the WHO-Diabetes Treatment Satisfaction Questionnaire (WHO-DTSQ).
Diabetes Nutr Metab. 17:235-43; 2004.
- 33) Targher G, Bertolini L, **Zoppini G**, Zenari L, Falezza G.
Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy.
Diabet Med. 22: 999-1004; 2005.
- 34) Targher G, Bertolini L, **Zoppini G**, Zenari L, Falezza G. Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients. Diabet Med. 22 :1146-50; 2005.
- 35) Targher G, Bertolini L, Scala L, **Zoppini G**, Zenari L, Falezza G.
Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue.
Diabet Med. 22:1354-8; 2005.
- 36) Trombetta M, Spiazzi G, **Zoppini G**, Muggeo M.
Type 2 diabetes and chronic liver disease in the Verona diabetes study.
Aliment Pharmacol Ther 2005; 22 Suppl 2: 24-7.
- 37) Targher G, Bertolini L, Padovani R, **Zoppini G**, Zenari L, Falezza G.
Associations between liver histology and carotid intima-media thickness in patients with nonalcoholic fatty liver disease.
Arterioscler Thromb Vasc Biol. 25: 2687-8; 2005.
- 38) Zanolini ME, Tosi F, **Zoppini G**, Castello R, Spiazzi G, Dorizzi R, Muggeo M, Moghetti P.
Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women.
Diabetes Care. 29: 372-8; 2006.

- 39) Targher G, Bertolini L, Rodella S, **Zoppini G**, Zenari L, Falezza G.
Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease.
Clin Endocrinol (Oxf). 64: 337-341; 2006.
- 40) Targher G, Bertolini L, Padovani R, Rodella S, **Zoppini G**, Zenari L, Cigolini M, Falezza G, Arcaro G.
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.
Diabetes Care. 2006; 29: 1325-30.
- 41) Targher G, Bertolini L, Rodella S, **Zoppini G**, Scala L, Zenari L, Falezza G. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.
Clin Endocrinol (Oxf). 2006; 64: 679-83.
- 42) Targher G, Bertolini L, Padovani R, Poli F, Scala L, Zenari L, **Zoppini G**, Falezza G. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients.
J Endocrinol Invest. 2006; 29: 55-60
- 43) **Zoppini G**, Targher G, Zamboni C, Venturi C, Cacciatori V, Moghetti P, Muggeo M.
Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes.
Nutr Metab Cardiovasc Dis 16: 543-9; 2006.
- 44) **Zoppini G**, Cacciatori V, Gemma ML, Moghetti P, Targher G, Zamboni C, Thomaseth K, Bellavere F, Muggeo M.
Effect of moderate aerobic exercise on sympatho-vagal balance in Type 2 diabetic patients.
Diabet Med 24: 370-6; 2007. I.F. 2.97
- 45) **Zoppini G**, Verlato G, Zamboni C, Venturi C, Gennaro N, Biasi V, Bonora E, Muggeo M.
Pulse Pressure and Mortality from Cerebrovascular Diseases in Type 2 Diabetic Patients: The Verona Diabetes Study.
Cerebrovasc Dis 23: 20-26; 2007. I.F. 2.534
- 46) Targher G, **Zoppini G**, Lippi G, Guidi GC, Muggeo M. Effect of serum gamma-glutamyltransferase and obesity on the risk of dyslipidemia and poor glycemic control in type 2 diabetic patients: cross-sectional findings from the Verona Diabetes Study.
Clin Chem 2007; 53: 1867-9; author reply 1869-70. I.F. 4.803
- 47) Targher G, Bertolini L, **Zoppini G**, Lippi G, Zenari L. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women: response to Juutilainen et al.
Diabetes Care 2007; 30: e51; author reply e52. I.F. 7.851

- 48) Luzi L, **Zoppini G**, Targher G, Battezzati A, Muggeo M, Bonora E. Insulin effect on serum potassium and auto-inhibition of insulin secretion is intact in a patient with leprechaunism despite severe impairment of substrates metabolism.
Diabetes Metab Res Rev. 2008; 29: 205-210. I.F. 3.087
- 49) Targher G, Montagnana M, Salvagno G, Moghetti P, **Zoppini G**, Muggeo M, Lippi G. Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients.
Clin Endocrinol 2008; 68: 481-484. I.F. 3.37
- 50) Lippi G, Targher G, Montagnana M, Salvagno GL, **Zoppini G**, Guidi GC. Relationship between red blood cell distribution width and kidney function tests in a large cohort of unselected outpatients.
Scand J Clin Lab Invest. 2008; 10: 1-4. I.F. 1.235
- 51) Chonchol M, Lippi G, Salvagno G, **Zoppini G**, Muggeo M, Targher G. Prevalence of Subclinical Hypothyroidism in Patients with Chronic Kidney Disease.
Clin J Am Soc Nephrol. 2008; 3: 1296-300 I.F. 2.236
- 52) Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, Franchini M, **Zoppini G**, Muggeo M. Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease.
J Am Soc Nephrol. 2008 Aug;19(8):1564-70. Epub 2008 Apr 2. I.F. 7.111
- 53) Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, **Zoppini G**, Muggeo M, Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men.
Obesity (Silver Spring) 2008; 16: 1394-9. I.F. 1.52
- 54) Targher G, **Zoppini G**, Muggeo M. Differential relationships between basal and post-load insulin resistance indices and hepatic fibrosis in chronic hepatitis C and in non-alcoholic fatty liver disease.
Gut 2008; 57: 426; author reply 426-7. I.F.10.015
- 55) Targher G, Bertolini L, Zenari L, Lippi G, Pichiri I, **Zoppini G**, Muggeo M, Arcaro G. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients.
Diabet Med 2008; 25: 45-50. I.F. 2.97
- 56) Targher G, Bertolini L, Rodella S, **Zoppini G**, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients.
Diabetologia 2008; 51: 444-50. I.F. 5.822
- 57) **Zoppini G**, Targher G, Trombetta M, Lippi G, Muggeo M. Relationship between soluble CD40 ligand and gamma-glutamyltransferase concentrations in non-drinking, young Type 1 diabetic individuals.
Diabet Med 25: 1283-8; 2008. I.F. 2.97

- 58) **Zoppini G**, Verlato G, Targher G, Bonora E, Trombetta M, Muggeo M. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. *Diabetes Metab Res Rev* 24: 624-8; 2008. I.F. 3.087
- 59) **Zoppini G**, Verlato G, Targher G, Casati S, Gusson E, Biasi V, Perrone F, Bonora E, Muggeo M. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? *Nutr Metab Cardiovasc Dis* 19: 334-9; 2009. I.F. 3.174
- 60) Targher G, **Zoppini G**, Cesare Guidi G, Lippi G. Relationship between serum bilirubin and kidney function in non-diabetic and diabetic individuals. *Kidney Int* 2009; 75 (8): 863. I.F. 4.922
- 61) **Zoppini G**, Targher G, Chonchol M, Perrone F, Lippi G, Muggeo M. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. *Nutr Metab Cardiovasc Dis* 19: 580-586; 2009. I.F. 3.174
- 62) **Zoppini G**, Targher G, Trombetta M, Lippi G, Muggeo M. Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. *Obesity (Silver Spring)* 17: 370-4; 2009. I.F. 1.52
- 63) Lippi G, Targher G, Montagnana M, Salvagno GL, **Zoppini G**, Guidi GC. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. *Arch Pathol Lab Med* 2009; 133: 628-32. I.F.1.806
- 64) Targher G, Chonchol M, Miele L, **Zoppini G**, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. *Semin Thromb Hemost* 2009; 35: 277-87. Review. I.F. 3.202
- 65) **Zoppini G**, Targher G, Negri C, Stoico V, Perrone F, Muggeo M, Bonora E. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. *Diabetes Care* 32: 1716-20; 2009. I.F. 7.851
- 66) Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, **Zoppini G**, Muggeo M, Day CP, Moghetti P. Abnormal Serum Alanine Aminotransferase Levels are Associated with Impaired Insulin Sensitivity in Young Women With Polycystic Ovary Syndrome. *J Endocrinol Invest* 2009; 32: 1716-1720. I.F. 2.021
- 67) Gisondi P, Targher G, **Zoppini G**, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. *J Hepatol.* 2009; 51: 758-64. I.F. 6.642

68) Lattuada E, Lanzafame M, **Zoppini G**, Concia E, Vento S. No influence of nevirapine on vitamin D deficiency in HIV-infected patients.

AIDS Res Hum Retroviruses 2009; 25: 849-50. I.F. 2.022

69) Tosi F, Dorizzi R, Castello R, Maffei C, Spiazzi G, **Zoppini G**, Muggeo M, Moghetti P. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome.

Eur J Endocrinol 2009; 161: 737-45. I.F. 3.239

70) Targher G, Chonchol M, **Zoppini G**, Salvagno G, Pichiri I, Franchini M, Lippi G.

Prevalence of thyroid autoimmunity and subclinical hypothyroidism in persons with chronic kidney disease not requiring chronic dialysis.

Clin Chem Lab Med 2009; 47: 1367-71. I.F. 1.57

71) Casati S, **Zoppini G**, Muggeo M, Marchini G.

Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism).

Eur J Ophthalmol 2010; 20: 224-7. I.F. 1.018

72) Targher G, Pichiri I, **Zoppini G**, Bonora E, Chonchol M.

Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review.

Semin Thromb Hemost 2009; 35: 605-12. Review. I.F. 3.202

73) **Zoppini G**, Targher G, Chonchol M, Negri C, Stoico V, Pichiri I, Lippi G, Muggeo M, Bonora E.

Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients.

Atherosclerosis 210: 575-80; 2010. I.F. 4.52

74) Targher G, **Zoppini G**, Chonchol M, Negri C, Stoico V, Perrone F, Muggeo M, Bonora E.

Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals.

Nutr Metab Cardiovasc Dis. 2010 Jan 20. [Epub ahead of print]

75) Targher G, Bertolini L, Chonchol M, Rodella S, **Zoppini G**, Lippi G, Zenari L, Bonora E.

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.

Diabetologia 2010; 53: 1341-8. I.F. 5.822

76) Targher G, **Zoppini G**, Moghetti P, Day CP.

Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver.

Semin Thromb Hemost 2010; 36: 41-8. Review. I.F. 3.202

- 77) **Zoppini G**, Targher G, Negri C, Stoico V, Gemma ML, Bonora E.
Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: role of kidney dysfunction.
Atherosclerosis 212: 287-91; 2010. I.F. 4.52
- 78) Targher G, Bertolini L, Padovani R, Rodella S, **Zoppini G**, Pichiri I, Sorgato C, Zenari L, Bonora E.
Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.
J Hepatol 2010; 53: 713-8. I.F. 6.642
- 79) Targher G, Bertolini L, Rodella S, Lippi G, **Zoppini G**, Chonchol M.
Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.
Clin J Am Soc Nephrol 2010; 5: 2166-71.
- 80) Targher G, Chonchol M, **Zoppini G**, Abaterusso C, Bonora E.
Risk of Chronic Kidney Disease in Patients With Non-Alcoholic Fatty Liver Disease: Is there a Link?
J Hepatol. 2010 Nov 17.
- 81) Targher G, **Zoppini G**, Day CP.
Risk of all-cause and cardiovascular mortality in patients with chronic liver disease.
Gut. 2011; 60: 1602-3.
- 82) Lanzafame M, Lattuada E, **Zoppini G**, Vento S.
Antiretroviral therapy-associated diseases are common in the long-term.
AIDS Res Hum Retroviruses. 2011; 27: 931-2.
- 83) Targher G, Chonchol M, **Zoppini G**, Franchini M.
Hemostatic disorders in type 1 diabetes mellitus.
Semin Thromb Hemost. 2011; 37: 58-65.
- 84) Bonora E, Kiechl S, Mayr A, **Zoppini G**, Targher G, Bonadonna RC, Willeit J. High-normal HbA1c is a strong predictor of type 2 diabetes in the general population.
Diabetes Care. 2011; 34: 1038-40.
- 85) Targher G, Chonchol M, Pichiri I, **Zoppini G**. Risk of Cardiovascular Disease and Chronic Kidney Disease in Diabetic Patients With Non-Alcoholic Fatty Liver Disease: Just a Coincidence?
J Endocrinol Invest 2011; 34: 544-51.
- 86) Bonora E, Kiechl S, **Zoppini G**, Targher G, Meigs JB, Willeit J, Oberhollenzer F, Bonadonna RC, Muggeo M.
Impact of Reference Category and Number of Traits in the Cluster on Risk of Coronary Heart Disease in Metabolic Syndrome: Prospective Data from the Bruneck Study.

Metab Syndr Relat Disord 2011; 9: 313-8.

87) **Zoppini G**, Negri C, Stoico V, Casati S, Pichiri I, Bonora E.

Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus.

Metabolism 2012; 61: 22-9.

88) Targher G, Pichiri I, **Zoppini G**, Trombetta M, Bonora E. Increased Prevalence of Cardiovascular Disease in Type 1 Diabetic Patients with Non-Alcoholic Fatty Liver Disease.

J Endocrinol Invest. 2011 Jul 27. [Epub ahead of print]

89) **Zoppini G**, Targher G, Bonora E.

The role of serum uric acid in cardiovascular disease in Type 2 diabetic and non-diabetic subjects: a narrative review.

J Endocrinol Invest 2011; 34: 881-6.

90) Targher G, Pichiri I, **Zoppini G**, Trombetta M, Bonora E.

Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver.

Diabet Med 2012; 29: 220-6.

91) **Zoppini G**, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.

Diabetes Care 35: 99-104; 2012.

92) Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, **Zoppini G**, Barbieri E, Targher G.

Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes.

Diabetes Care 2012; 35: 389-95.

93) **Zoppini G**, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, Bonora E.

Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function.

Clin J Am Soc Nephrol 7: 401-8; 2012.

94) Bacchi E, Negri C, Zanolin ME, Milanese C, Faccioli N, Trombetta M, **Zoppini G**, Cevese A, Bonadonna RC, Schena F, Bonora E, Lanza M, Moghetti P.

Metabolic Effects of Aerobic Training and Resistance Training in Type 2 Diabetic Subjects: A randomized controlled trial (the RAED2 study).

Diabetes Care 2012; 35: 676-82.

95) Mantovani A, **Zoppini G**, Targher G, Golia G, Bonora E.

Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals.

J Endocrinol Invest 2012; 35: 215-8.

- 96) Rossi A, Targher G, **Zoppini G**, Cicoira M, Bonapace S, Negri C, Stoico V, Faggiano P, Vassanelli C, Bonora E. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. *Diabetes Care* 2012; 35: 1781-6.
- 97) Targher G, **Zoppini G**, Mantovani W, Chonchol M, Negri C, Stoico V, Mantovani A, De Santi F, Bonora E. Comparison of Two Creatinine-Based Estimating Equations in Predicting All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes. *Diabetes Care* 2012; 35: 2347-53.
- 98) Pugliese G, Solini A, **Zoppini G**, Fondelli C, Zerbini G, Vedovato M, Cavalot F, Lamacchia O, Buzzetti R, Morano S, Nicolucci A, Penno G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group. High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. *Diabetes Res Clin Pract* 2012; 98: 329-37.
- 99) Penno G, Solini A, **Zoppini G**, Orsi E, Zerbini G, Trevisan R, Gruden G, Cavalot F, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. *Diabetes Care* 2012; 35: 2317-23.
- 100) Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, **Zoppini G**, Mantovani W, Barbieri E, Byrne CD. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. *PLoS One* 2013; 8: e57183. doi: 10.1371/journal.pone.0057183. Epub 2013 Feb 22.
- 101) Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, **Zoppini G**, Zanolin E, Schena F, Bonora E, Moghetti P. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). *Hepatology* 2013; 58: 1287-95.
- 102) Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, **Zoppini G**, Morani G, Vassanelli C, Bonora E. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. *Clin Sci (Lond)* 2013; 125: 301-9.
- 103) Valbusa F, Bertolini L, Bonapace S, Zenari L, **Zoppini G**, Arcaro G, Byrne CD, Targher G. Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus.

Am J Cardiol 2013; 112: 499-504.

104) Penno G, Solini A, **Zoppini G**, Orsi E, Fondelli C, Zerbini G, Morano S, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group.

Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol 2013; 12: 98.

105) Cioffi G, Rossi A, **Zoppini G**, Targher G, de Simone G, Devereux RB, Vassanelli C, Bonora E.

Inappropriate left ventricular mass independently predicts cardiovascular mortality in patients with type 2 diabetes. Int J Cardiol 2013; 168: 4953-6.

106) Squintani G, **Zoppini G**, Donato F, Pineschi E, Donini D, Stoico V, Moretto G, Bonora E, Morini A.

Antidromic sensory nerve conduction study of the digital branches of the medial plantar nerve: A novel method to detect early diabetic sensory axonal polyneuropathy.

Muscle Nerve 2013 Nov 26. doi: 10.1002/mus.24135. [Epub ahead of print]

107) **Zoppini G**, Galletti A, Targher G, Brangani C, Pichiri I, Negri C, Stoico V, Cacciatori V, Bonora E.

Glycated haemoglobin is inversely related to serum vitamin D levels in type 2 diabetic patients. PLoS One 2013; 8: e82733.

108) Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, Bishop L, Bonora E, Bunnag P, Chuang LM, Deerochanawong C, Goldenberg R, Harshfield B, Hernández C, Herzlinger-Botein S, Itoh H, Jia W, Jiang YD, Kadowaki T, Laranjo N, Leiter L, Miwa T, Odawara M, Ohashi K, Ohno A, Pan C, Pan J, Pedro-Botet J, Reiner Z, Rotella CM, Simo R, Tanaka M, Tedeschi-Reiner E, Twum-Barima D, **Zoppini G**, Carey VJ.

Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.

Circulation 2014; 129: 999-1008.

109) Cioffi G, Rossi A, Targher G, **Zoppini G**, de Simone G, Devereux RB, Bonora E, Vassanelli C.

Usefulness of subclinical left ventricular midwall dysfunction to predict cardiovascular mortality in patients with type 2 diabetes mellitus.

Am J Cardiol 2014; 113: 1409-14.

110) Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Pichiri I, Mantovani A, **Zoppini G**, Bonora E, Barbieri E, Byrne CD.

Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes.

Nutr Metab Cardiovasc Dis 2014 Jan 21. pii: S0939-4753(14)00012-X. doi: 10.1016/j.numecd.2014.01.005. [Epub ahead of print]

111) Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, Pancheri S, Trombetta M, **Zoppini G**, Chonchol M, Byrne CD, Bonora E.

Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Chronic Kidney Disease in Patients With Type 1 Diabetes.

Diabetes Care 2014 Apr 2. [Epub ahead of print]

112) **Zoppini G**, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E.

Mortality from chronic liver diseases in diabetes.

Am J Gastroenterol. 109:1020-5; 2014.

113) Targher G, **Zoppini G**, Bonora E, Moghetti P.

Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome.

Semin Thromb Hemost. 2014 Jul 7. [Epub ahead of print]

114) Nadalini L, Zenti MG, Masotto L, Indelicato L, Fainelli G, Bonora F, Battistoni M, Romani B, Genna M, **Zoppini G**, Bonora E. Improved Quality of Life after bariatric surgery in morbidly obese patients. Interdisciplinary group of bariatric surgery of Verona (G.I.C.O.V.).

G Chir. 2014 Jul-Aug; 35 (7-8):161-4

115) Solini A, **Zoppini G**, Orsi E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Arosio M, Baroni MG, Penno G, Pugliese G; for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.

Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications.

J Hypertens. 2014 Sep 5. [Epub ahead of print]

LAVORI MULTICENTRICI SU RIVISTE CENSITE SU CURRENT CONTENTS DOVE SI COMPARE SOLO FRA I PARTECIPANTI ALLO STUDIO

1) Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.

Clinical significance of nonalbuminuric renal impairment in type 2 diabetes.

J Hypertens 2011; 29: 1802-9.

2) Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events Study Group.

HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study.

Diabetes Care 2013; 36: 2301-10.

3) Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) study, group.

Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study.

J Intern Med 2013; 274: 176-91.

4) Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Penno G; RIACE Study Group.

Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.

Cardiovasc Diabetol 2014; 13: 59.

LAVORI SU RIVISTE INTERNAZIONALI NON CENSITE DA CURRENT CONTENTS

1) **G.Zoppini**, P.Galante, M.Zardini, M.Muggeo

Antiphosphotyrosine antibodies: preparation and applications.

Eur J Lab Med 1: 101-103, 1993

2) Kahn C.R., Araki E., Saad M.J., Folli F., **Zoppini G.** and Huertas P.

Molecular Aspects of Insulin Action, Insulin Resistance and Their Relationship to Atherosclerosis.

Atherosclerosis Reviews 25:209-223, 1993

3) **Zoppini G.**, Galante P., Ferrari S., Trevisan M.T., Zardini M., Muggeo M.

Relation between palmitic acid concentration in the erythrocyte membranes and insulin binding.

Eur J Lab Med 3:15-18, 1995

4) M.Muggeo and **G.Zoppini**. Type 2 diabetes in the elderly: practical considerations.

Medicographia 78, vol 26: 45-53; 2004.

LAVORI PUBBLICATI IN LIBRI O ATTI DI CONGRESSI INTERNAZIONALI (NO ABSTRACT)

1) Moghetti P., Querena M., Stanzial A., Bonora E., Cacciatori V., **Zoppini G.**, Crepaldi G., Muggeo M.

Growth hormone response to insulin in type I diabetics with and without retinopathy.

In: Microvascular and Neurological Complications of Diabetes. Crepaldi G., Cuhna-Vaz J.C., Fedele D., Mogensen C.E., Ward J.C., eds. Liviana Press, Padova, pag. 71, 1987

2) **Zoppini G.**, Galante P., Zardini M. and Muggeo M.

Phosphotyrosine protein profiles in monocytes stimulated by insulin and IGF-1.

Exp.Clin.Endocrinol. 101 (suppl.2):200-201, 1993

LAVORI PUBBLICATI SU RIVISTE ITALIANE

- 1) M.Muggeo, **G.Zoppini**. Attività fisica e diabete mellito.
G It Diabetol 13: 397-406, 1993

- 2) **G. Zoppini**, M.Muggeo. La prescrizione dell'attività fisica nel paziente diabetico.
Medico & Metabolismo. Anno 7° n.1: 33-37; 2003.

- 3) **G. Zoppini**, M.Muggeo. Diabete e tumori. Confronto dei risultati del Verona Diabetes Study alla luce della letteratura corrente.
Medico & Metabolismo. Anno 8, n.1: 41-44; 2004.

- 4) **G.Zoppini**, G.Verlato. Mortalità nel diabete.
Il Diabete 16: 300-316; 2004

- 5) M.Muggeo, **G.Zoppini**, G.Targher. Il diabete tipo 2 nell'anziano.
Quaderni di diabetologia nella pratica clinica. 2008; 2: 31-40.

LAVORI PUBBLICATI IN LIBRI O ATTI DI CONGRESSI ITALIANI (NO ABSTRACT)

1) Bonora E., Moghetti P., Querena M., Cigolini M., Cacciatori V., **Zoppini G.**, Muggeo M.

Livelli plasmatici di C-peptide e glucagone in soggetti obesi durante clamp iperglicemico con e senza infusione di somatostatina.

In: *Obesità '88. Fisiopatologia, Clinica e Terapia*. Melchionda N., Enzi G., Bosello O., eds. L. Parma Editrice, Bologna 1989, pag. 435

CAPITOLI DI LIBRI ITALIANI E MONOGRAFIE

1) Muggeo M. e **Zoppini G.**

La resistenza insulinica

Il diabete non insulino dipendente Eziopatogenesi e Terapia

In Quaderni di Castel Ivano pag 44-53: 1990

2) Muggeo M., **Zoppini G.**

Insulin receptors and insulin action.

Update on Diabetes Childhood. 3rd International Course, Editoriale Bios: 41-46, 1991

3) Muggeo M., **Zoppini G.**, Bonora E.

La terapia insulinica.

AMT - XLV Giornate Mediche Triestine. ed. O.C.T., 83-87, 1991

4) **Zoppini G.** Mortalità e morbilità cardiovascolare nella popolazione diabetica. In Iperglicemia post-prandiale e rischio cardiovascolare. Upgraded Novo Nordisk. pp. 11-23, 2000.

5) Muggeo M., Brun E., **Zoppini G.** Diabete mellito e continuità assistenziale. In Rapporto Sanità 2001, la continuità assistenziale. A cura di Falcitelli N., Trabucchi M., 2 Vanara F. Società Editrice il Mulino. Pp. 395-410, 2001.

6) Muggeo M., **Zoppini G.**, Brun E., Bonora E., Verlatto G. Mortality and its predictors in type 2 diabetes. pp 101-117. In Diabetes in old Age. Second edition. Edited by A.J.Sinclair and P.Finucane. John Wiley & Sons Ltd. 2001.

7) **G.Zoppini** e G. Calori. La mortalità: quali informazioni da quali studi. In Manuale pratico di epidemiologia e metodologia. Pacini Editore. pp 25-35 2001.

8) **G.Zoppini** . Alterazioni metaboliche e neoplasie. In Dalla resistenza insulinica al rischio globale. Pacini Editore. pp 31-37 2007.

9) **G.Zoppini**, Enzo Bonora. Il rischio residuo microvascolare nel diabete. In “Approccio mirato al rischio residuo microvascolare nel paziente diabetico”. Primula Edizioni. pp: 7-22, 2011.

10) **G.Zoppini**, G.Verlatto. Mortalità nel diabete mellito tipo 2. In “IL DIABETE IN ITALIA. Editor Graziella Bruno. A cura del gruppo di studio Epidemiologia, Costi e Qualità, Società Italiana di Diabetologia. Edizioni Minerva Medica. pp: 79-85, 2012.